BREAKTHROUGH THERAPIES FOR
PULMONARY ARTERIAL HYPERTENSION
OUR SCIENCE
APaxen’s R&D is focused on research and development of breakthrough therapeutics for the treatment of diseases associated with chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases, including IPF and PH-IPF.
PIPELINE
Apaxen has a robust pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation.
Pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases are the primarily targeted indications.
LATEST NEWS & PUBLICATIONS
Apaxen appoints Graham K. Dixon as Chairman and prepares for clinical testing of its lead inflammasome inhibitor
Gosselies, Belgium, July 18, 2022 – Apaxen S.A., a privately-held biotechnology company, developingnovel next generation NLRP3 inflammasome inhibitor drugs for treatment of chronic inflammatoryand auto-immune…
Belgian biotech Apaxen appoints Bart Wuurman as CEO
Gosselies, Belgium, November 12, 2020 – Apaxen S.A., a privately-held preclinical stage biotechnology company, developing novel oral drugs for chronic inflammatory diseases, with a primary…
PR – Apaxen raises €3.3 million in Series A Financing
Apaxen raises €3.3 million in Series A Financing to Develop Breakthrough Anti-inflammatory Therapeutics for Pulmonary Arterial Hypertension.